[{"orgOrder":0,"company":"adMare BioInnovations","sponsor":"BELLUS Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"adMare BioInnovations","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"adMare BioInnovations \/ Bellus Health ","highestDevelopmentStatusID":"8","companyTruncated":"adMare BioInnovations \/ Bellus Health "},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Jefferies"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Jefferies"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"BLU-5937","moa":"P2X3 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"},{"orgOrder":0,"company":"BELLUS Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"BLU-5937","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"BELLUS Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"BELLUS Health \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BELLUS Health \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for BLU-5937

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. It is being developed for the treatment of refractory chronic cough.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 08, 2023

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 10, 2022

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 22, 2022

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the Supplement (as defined below).

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 18, 2022

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Jefferies

                          Deal Size : $153.0 million

                          Deal Type : Public Offering

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The Company intends to use the net proceeds of the offering primarily to fund BLU-5937 research and development activities, working capital needs and other general corporate purposes, as set out in the supplement.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 14, 2022

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Jefferies

                          Deal Size : $153.0 million

                          Deal Type : Public Offering

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BLU-5937 is a potent P2X3 receptor antagonist with high selectivity for P2X3 (>1500 fold) over P2X2/3. In healthy volunteers, BLU-5937 showed good drug and pharmacokinetic characteristics, for the treatment of refractory chronic cough.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 02, 2022

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Phase 2b SOOTHE trial which highlight BLU-5937 was well-tolerated with a low rate of taste-related adverse events (?6.5%) treatment emergent adverse event profile comparable to placebo used for the treatment of refractory chronic cough.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          December 13, 2021

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : BLU-5937, a highly selective P2X3 antagonist, is in development for RCC, chronic pruritus and other hypersensitization-related disorders.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 23, 2021

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The SOOTHE Phase 2b trial is planned as a multicenter, randomized, double-blind, 4-week, parallel arm study evaluating three doses of BLU-5937 (12.5 mg, 50 mg and 200 mg BID) in 280 patients with refractory chronic cough versus placebo.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 08, 2020

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Primary endpoint of placebo-adjusted reduction in awake cough frequency did not reach statistical significance. BLU-5937 was well tolerated with low impact on taste perception; safety profile comparable to placebo.

                          Brand Name : BLU-5937

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 06, 2020

                          Lead Product(s) : BLU-5937

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank